Integrative Biomedical Research

1. Introduction

Alzheimer’s disease remains, by almost any measure, one of the more stubborn problems in modern medicine — a slow erosion of memory and personhood that now stands as the leading cause of dementia worldwide, touching tens of millions of people and straining health systems in ways few policymakers fully anticipated a generation ago (Al Khzem & Gomaa, 2026; Arar et al., 2023; Dominguez-Gortaire et al., 2025). Pathologically, the disease is defined by two intertwined but structurally distinct lesions: extracellular senile plaques built from aggregated amyloid-beta (Aβ) peptides, and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein (Dominguez-Gortaire et al., 2025; Jiang et al., 2025; Job et al., 2023). For the better part of three decades, drug discovery gravitated almost exclusively toward the first of these lesions — the amyloid cascade hypothesis — on the reasoning, plausible enough at the time, that slowing Aβ production or accelerating plaque clearance would necessarily translate into preserved cognition (Al Khzem & Gomaa, 2026; Arar et al., 2023; Mella et al., 2026).

That reasoning has not entirely held up, or at least not as cleanly as hoped. The FDA-approved symptomatic drugs that emerged from this era of research — acetylcholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, together with the NMDA-receptor antagonist memantine — ease symptoms modestly and temporarily, without altering the underlying neurodegenerative trajectory in any meaningful sense (Al Khzem & Gomaa, 2026; Arar et al., 2023; Jiang et al., 2025). Even the newer disease-modifying antibodies — aducanumab, lecanemab, and donanemab — which do measurably clear amyloid plaque from the brain, have produced only modest effects on the actual slope of cognitive decline, and they carry a non-trivial risk of amyloid-related imaging abnormalities (ARIA) that complicates their use in everyday clinical practice (Al Khzem & Gomaa, 2026; Arar et al., 2023; Masri, 2026). It is against this somewhat sobering backdrop that therapeutic attention has pivoted, gradually but rather decisively, toward tau. Part of the appeal is empirical rather than theoretical: across autopsy and fluid-biomarker studies alike, tau pathology tracks far more tightly with synaptic loss, cortical atrophy, and the clinical trajectory of cognitive impairment than amyloid burden ever has (Al Khzem & Gomaa, 2026; Arar et al., 2023; Dominguez-Gortaire et al., 2025).

Under ordinary physiological conditions, tau is an unassuming, soluble, intrinsically disordered protein encoded by the MAPT gene, whose principal job is to stabilize axonal microtubules and keep intracellular trafficking running smoothly (Arar et al., 2023; Cehlar et al., 2024; Job et al., 2023). Disease changes this picture considerably. Dysregulated kinase signaling — driven predominantly by glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (CDK5) — drives tau hyperphosphorylation across dozens of serine, threonine, and tyrosine residues, and the protein responds by detaching from microtubules and accumulating, somewhat inappropriately, within the somatodendritic compartment of the neuron (Arar et al., 2023; Jiang et al., 2025; Job et al., 2023). Once detached, misfolded tau begins to self-assemble, and it does so in a fairly targeted way: two hexapeptide motifs embedded within the microtubule-binding repeat region — ₂₇₅VQIINK₂₈₀ in the R2 segment and ₃₀₆VQIVYK₃₁₁ in the R3 segment — act as the principal nucleation hotspots, folding into cross-β sheet architectures and steric zippers that give the resulting fibrils their mechanical stability (Al Khzem & Gomaa, 2026; Cehlar et al., 2024; Job et al., 2023). The soluble oligomers formed during this early nucleation phase, rather than the mature fibrils themselves, appear to be the chief neurotoxic culprits — disrupting synaptic plasticity, inducing mitochondrial dysfunction, and spreading between connected neurons through a trans-synaptic, prion-like seeding mechanism that has become one of the more unsettling findings in recent tau biology (Arar et al., 2023; Cehlar et al., 2024; Habtemariam, 2026).

For a long time, structure-based drug design simply could not get much traction against tau, precisely because tau behaves as an intrinsically disordered protein and lacks the fixed tertiary fold that most rational-design pipelines depend on (Arar et al., 2023; Cehlar et al., 2024; Masri, 2026). The picture changed, rather dramatically, with the maturation of cryogenic electron microscopy (cryo-EM), which finally made it possible to resolve tau amyloid filaments extracted directly from patient brain tissue at near-atomic resolution (Arar et al., 2023; Taylor & Radford, 2026). What emerged from these structures was not a single, tidy fold but a striking degree of polymorphism: the identical amino acid sequence, it turns out, can assemble into markedly different, highly ordered filament architectures depending on the disease context — paired helical filaments and straight filaments in Alzheimer’s disease, and quite distinct folds in chronic traumatic encephalopathy, Pick’s disease, and corticobasal degeneration (Arar et al., 2023; Cehlar et al., 2024; Taylor & Radford, 2026). Time-resolved cryo-EM has since pushed this picture further still, suggesting that disease-specific filaments do not simply appear fully formed but nucleate from a shared structural ancestor — termed the first intermediate amyloid (FIA) — before undergoing solvent-guided refinement into the mature, disease-defining protofilament folds (Cehlar et al., 2024; Taylor & Radford, 2026). Taken together, these atomic-resolution maps of the polymorphic assembly landscape give structural biologists, for the first time, a genuine foothold for designing targeted anti-aggregation therapeutics (Arar et al., 2023; Taylor & Radford, 2026).

Running roughly in parallel to these experimental advances — and arguably amplifying their impact — has been the rise of deep-learning structure prediction. AlphaFold, AlphaFold 2, AlphaFold 3, and RoseTTAFold have, in the space of a few years, reshaped what structural biology and drug discovery can accomplish (Cehlar et al., 2024; Esmaeilpour et al., 2026; Jumper et al., 2021). By predicting three-dimensional protein folds, macromolecular interfaces, and proteoform-specific variation directly from primary sequence, these platforms have considerably shortened the path from target identification to virtual screening (Esmaeilpour et al., 2026; Jiang et al., 2025). In tau research specifically, AlphaFold-assisted modeling now underpins the rational design of a genuinely diverse therapeutic portfolio: small organic molecules such as piperidine-substituted benzaldehydes, coumarins, and pyrazole hybrids; peptidomimetic capping agents and retro-inverso peptides, including RI-AG03, engineered to dual-cap the ₂₇₅VQIINK₂₈₀ and ₃₀₆VQIVYK₃₁₁ hotspots simultaneously; bispecific nanobodies; and proteolysis-targeting chimeras (PROTACs) designed for selective intracellular tau degradation (Abskharon et al., 2023; Al Khzem & Gomaa, 2026; Jiang et al., 2025; Job et al., 2023). AI frameworks have also enabled a more ambitious style of drug design altogether — multitarget-directed ligands (MTDLs) that are engineered from the outset to act on several pathogenic nodes at once, combining tau anti-aggregation activity with kinase inhibition, Aβ-directed activity, or anti-inflammatory effects within a single molecular entity (Al Khzem & Gomaa, 2026; Job et al., 2023; Mella et al., 2026; Setiawan et al., 2026).

None of this, it should be said, amounts to a solved problem. Applying AI structure-prediction tools to disordered protein aggregation still runs into real limitations (Al Khzem & Gomaa, 2026; Cehlar et al., 2024). Because AlphaFold-type models were trained predominantly on static, well-ordered proteins drawn from public structural databases, they struggle — perhaps unsurprisingly — when asked to capture the dynamic conformational ensembles characteristic of intrinsically disordered proteins, liquid–liquid phase separation condensates, and environment-dependent fibril polymorphs (Al Khzem & Gomaa, 2026; Taylor & Radford, 2026). More concerning still, state-of-the-art tools such as AlphaFold 3 exhibit chiral violation rates approaching 51% when modeling D-amino acid peptides, a therapeutic class of real importance for amyloid capping strategies, which makes plain the continued necessity of pairing AI predictions with atomistic molecular dynamics simulations, quantitative structure–activity relationship modeling, and rigorous experimental validation rather than treating a predicted structure as a finished answer (Al Khzem & Gomaa, 2026; Esmaeilpour et al., 2026).

With that context in mind, this review sets out to take stock of where structure-based, AI-guided drug design for tau aggregation actually stands, and where it still needs to go. More specifically, we aim to summarize the pathophysiological mechanisms and structural biology underlying tau aggregation, tracing the conformational transition from the monomeric, intrinsically disordered state through neurotoxic oligomers and intermediate assemblies to mature, polymorphic fibril folds in Alzheimer’s disease, to evaluate how cryo-EM and AI-driven structure-prediction platforms — AlphaFold, AlphaFold 3, and RoseTTAFold among them — have mapped atomic-resolution tau structures, identified druggable steric-zipper interfaces, and modeled the macromolecular complexes relevant to therapeutic design; to critically review the principal structure-based drug design strategies now being pursued against tau, spanning small-molecule inhibitors, dual Aβ/tau aggregation blockers, retro-inverso and cyclic peptides, nanobodies, and tau-selective PROTACs; to examine the computational bottlenecks and translational obstacles that continue to slow this field, including the prediction of disordered ensembles, chiral D-peptide modeling errors, blood–brain barrier permeability, and metabolic stability; and tooutline a plausible, decade-scale roadmap for integrating generative AI, molecular dynamics simulation, and high-throughput experimental validation in order to move disease-modifying tau therapeutics closer to clinical reality.

2. AI-Guided Structural Biology and Targeted Degradation Strategies for Tau Pathology in Alzheimer's Disease

The sections that follow work through this landscape in roughly the order a structural biologist would encounter it: first the disease biology itself, then the computational tools now used to visualize it, then the therapeutic modalities those tools have made possible, and finally the delivery and translational obstacles that still stand between a promising structure and an actual medicine.

2.1. Pathophysiological Foundations: From Intrinsically Disordered Tau to Polymorphic Fibril Assemblies

Alzheimer’s disease is, at its structural core, a disease of two aggregating proteins — extracellular amyloid-beta plaques and intracellular neurofibrillary tangles — and although both have received enormous attention, the clinical evidence increasingly favors tau as the more proximate driver of neurodegeneration (Dominguez-Gortaire et al., 2025; Jiang et al., 2025). Decades of therapeutic effort were poured into the amyloid cascade hypothesis, not unreasonably given the genetics of early-onset familial disease, yet longitudinal and neuropathological studies keep returning the same finding: it is the spread of tau pathology, not amyloid burden, that correlates most strongly with synaptic loss, cortical atrophy, and the clinical slope of cognitive decline (Al Khzem & Gomaa, 2026; Arar et al., 2023).

Tau itself is encoded by the MAPT gene on chromosome 17 and exists, under normal conditions, as a soluble intrinsically disordered protein — a somewhat unusual state of affairs for a protein whose job depends on precise molecular interactions (Cehlar et al., 2024). Rather than folding into one fixed shape, healthy tau samples a broad conformational ensemble that stabilizes axonal microtubules and supports motor-protein-mediated transport along the axon (Cehlar et al., 2024; Job et al., 2023). Alternative splicing of exons 2, 3, and 10 generates six distinct isoforms in the adult human brain, distinguished chiefly by whether they carry three (3R) or four (4R) microtubule-binding repeats — a detail that turns out to matter a great deal, since different tauopathies show marked isoform-specific inclusion patterns (Cehlar et al., 2024).

Disease intervenes at the level of phosphorylation. Dysregulated kinase activity — glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase 5 (CDK5), protein kinase A, and protein kinase C chief among the culprits — drives hyperphosphorylation across roughly eighty candidate serine, threonine, and tyrosine residues (Job et al., 2023; Setiawan et al., 2026). The consequence is fairly direct: hyperphosphorylation weakens tau’s electrostatic grip on microtubules, the protein detaches, and it relocates — somewhat inappropriately — into the somatodendritic compartment of the neuron (Arar et al., 2023; Job et al., 2023). From there, monomeric tau misfolds and self-assembles, passing through soluble oligomers and protofibrils on its way to mature paired helical filaments (PHFs) and straight filaments (SFs) (Cehlar et al., 2024; Taylor & Radford, 2026). Two hexapeptide motifs within the microtubule-binding repeat region do most of the structural work here: ₂₇₅VQIINK₂₈₀, in the R2 segment, and ₃₀₆VQIVYK₃₁₁ — often called PHF6 — in the R3 segment (Al Khzem & Gomaa, 2026; Job et al., 2023). Both motifs nucleate inter- and intra-protofilament steric zippers and cross-β sheet spines that ultimately stabilize the hydrophobic core running through the length of a mature tau filament (Cehlar et al., 2024; Taylor & Radford, 2026). Figure 1 traces this cascade schematically, from the physiological monomer through hyperphosphorylation-driven detachment, oligomer formation, and the recently characterized intermediate species described below, to the polymorphic, disease-specific filament folds that close out the pathway.

It is cryo-EM, more than any single technique, that has rewritten this part of the story. Reconstructions of filaments extracted directly from patient brain tissue reveal that tau exhibits genuine structural polymorphism — the same primary sequence folding into distinct, highly ordered amyloid architectures depending on the neurodegenerative context (Arar et al., 2023; Taylor & Radford, 2026). Alzheimer’s disease is characterized by C-shaped protofilament folds that assemble into PHFs and SFs, whereas chronic traumatic encephalopathy, Pick’s disease, corticobasal degeneration, and progressive supranuclear palsy each display their own distinct filament topology (Cehlar et al., 2024; Taylor & Radford, 2026). Time-resolved cryo-EM work by Lövestam et al. (2024) has since added a kinetic dimension to this structural picture, showing that both Alzheimer’s and chronic traumatic encephalopathy tau filaments nucleate from a shared structural ancestor — the ‘first intermediate amyloid,’ or FIA (Cehlar et al., 2024; Taylor & Radford, 2026). FIA is, in essence, an antiparallel dimer stabilized by a tight cross-β interface centered on the ₃₀₆VQIVYK₃₁₁ segment; over time, it undergoes secondary nucleation and solvent-guided structural refinement, gradually maturing into the disease-specific protofilament folds recovered from postmortem tissue (Cehlar et al., 2024; Taylor & Radford, 2026). Whether this common-intermediate model generalizes across the full spectrum of tauopathies remains, admittedly, an open question — but it already offers a genuinely new handle for intervention, since a therapeutic capable of intercepting tau before it commits to a disease-specific fold might, in principle, prove effective across several tauopathies at once.

Figure 1. The Tau Aggregation Cascade: From Physiological Monomer to Polymorphic Disease-Specific Fibrils.   This Figure trace the pathological transformation of tau from a soluble, intrinsically disordered microtubule-associated monomer into mature, disease-specific amyloid fibrils. Kinase-driven hyperphosphorylation (GSK-3β, CDK5) first causes tau to detach from microtubules and relocate to the somatodendritic compartment, after which self-assembly through the ₂₇₅VQIINK₂₈₀ and ₃₀₆VQIVYK₃₁₁ hexapeptide hotspots generates neurotoxic soluble oligomers. These oligomers nucleate into the recently characterized first intermediate amyloid (FIA), an antiparallel dimeric species that subsequently undergoes solvent-guided structural maturation into the polymorphic, tauopathy-specific protofilament folds — including paired helical and straight filaments in Alzheimer’s disease.

Figure 2. AI-Driven Structural Biology and Network Analysis Workflow for Tau Drug Discovery. This figure  summarizes the computational pipeline by which primary tau sequence and post-translational modification data are converted into actionable drug-design inputs. Multiple sequence alignment and evolutionary covariation data feed deep-learning architectures such as AlphaFold 3 and RoseTTAFold, which generate both static atomic coordinates (steric-zipper and binding-pocket geometry) and, through downstream Residue Interaction Network analysis, allosteric and rigidity maps of the protein. These two complementary structural outputs converge on an integrated drug-discovery workflow encompassing virtual screening, peptidomimetic design, and PROTAC development.

2.2. The Deep Learning Revolution: Structure Prediction and Network Structural Biology

Structure-based drug design against tau was, for a long time, held back less by a lack of ambition than by a lack of tools. Traditional biophysical methods — X-ray crystallography in particular, and to a lesser extent solution NMR — simply were not built to resolve the dynamic, heterogeneous conformational ensembles that intrinsically disordered proteins like tau adopt (Arar et al., 2023; Jeyaraj et al., 2025). What eventually broke this bottleneck was not a single breakthrough so much as a wave of deep-learning architectures: AlphaFold, AlphaFold 2, AlphaFold 3, and RoseTTAFold, each building on the last (Esmaeilpour et al., 2026; Jeyaraj et al., 2025; Jumper et al., 2021). By extracting evolutionary covariation signals from multiple sequence alignments and integrating them with spatial geometric modules — the Evoformer architecture being the best known — these platforms can now predict three-dimensional protein folds directly from primary sequence with a level of accuracy that would have seemed implausible a decade ago (Jeyaraj et al., 2025; Jiang et al., 2025). AlphaFold 3 extended this further still, moving toward unified multimodal prediction capable of modeling proteins alongside nucleic acids, small-molecule ligands, ions, and post-translationally modified residues within a single framework (Fang et al., 2025; Jeyaraj et al., 2025).

Complementary tools have opened up adjacent questions. Deep-learning platforms such as D-I-TASSER now support structural annotation of specific proteoforms — the individual protein variants produced by mutation, alternative splicing, or post-translational modification — which, in tau research, allows computational chemists to ask how a particular phosphorylation, acetylation, or truncation event reshapes local backbone flexibility and promotes β-sheet-prone, aggregation-competent conformations (Fang et al., 2025; Setiawan et al., 2026). To capture the higher-order topology that emerges from these local changes, structural biologists have increasingly turned to Residue Interaction Networks (RINs), which represent individual amino acids as nodes and their non-covalent contacts — van der Waals interactions, hydrogen bonds, salt bridges, π–π stacking — as edges (Miotto et al., 2025; Tosatto et al., 2025). Network metrics derived from this representation, including degree centrality, betweenness centrality, and average shortest path length, offer a reasonably direct way to quantify structural rigidity, trace allosteric communication pathways, and flag mutation-sensitive hotspots across a protein assembly (Miotto et al., 2025; Tosatto et al., 2025). Figure 2 sketches how these pieces typically fit together in practice: primary sequence and post-translational modification data feed a deep-learning prediction step, which in turn generates both static atomic coordinates and residue interaction graphs that jointly inform downstream drug discovery workflows.

None of this, it must be said plainly, has fully solved the disordered-protein problem — and arguably it was never going to. Because AlphaFold-family models are trained predominantly on the well-ordered, crystallographically resolved structures deposited in the Protein Data Bank, they continue to struggle with intrinsically disordered regions, with liquid–liquid phase separation condensates, and with fibril polymorphs whose folds shift with solution conditions (Jeyaraj et al., 2025; Taylor & Radford, 2026). For disordered regions specifically, per-residue confidence scores — the predicted Local Distance Difference Test, or pLDDT — routinely fall below 50, which reflects genuine conformational mobility rather than a modeling failure as such, though it is easy to conflate the two if one is not careful (Jeyaraj et al., 2025). More troubling, at least for peptide-based therapeutics, is that AlphaFold 3 shows chiral violation rates near 51% when modeling D-amino acid peptides, a limitation of real consequence given that D-peptides represent a leading therapeutic class for amyloid capping strategies (Al Khzem & Gomaa, 2026). The practical upshot is that AI-generated structures are best treated as testable hypotheses rather than finished answers, requiring cross-validation through molecular dynamics simulation, hydrogen–deuterium exchange mass spectrometry, and cryo-EM before any real confidence can be placed in them (Fang et al., 2025; Jeyaraj et al., 2025).

2.3. Structure-Guided Inhibitor Modalities: Small Molecules, Peptidomimetics, and Multitarget-Directed Ligands

With atomic-resolution tau structures finally in hand, medicinal chemists have pursued a genuinely broad range of chemical strategies, spanning small organic molecules, peptidomimetics, engineered antibody fragments, and multitarget-directed ligands (Al Khzem & Gomaa, 2026; Job et al., 2023; Masri, 2026). On the small-molecule side, Job et al. (2023) designed and evaluated a series of seven piperidine-substituted 3-nitrobenzaldehyde derivatives, labeled L1 through L7, using extensive in silico docking and molecular dynamics. Docking against the ₂₇₅VQIINK₂₈₀ segment (PDB ID: 5V5B) identified compound L3 as the strongest candidate, binding with notable affinity to the charged residues Lys280 and Lys281 — an interaction that appeared to interfere with primary nucleation and destabilize pre-formed oligomeric seeds, while the compound also retained reasonably favorable blood–brain barrier permeability characteristics (Job et al., 2023). A rather different chemotype, natural coumarin derivatives, works by a complementary mechanism: these rigid, planar scaffolds intercalate directly into the cross-β fibril groove through π–π stacking and hydrophobic contacts, and several synthetic pyrazole and pyrazolopyridine hybrids extend this idea further by simultaneously inhibiting GSK-3β kinase activity while interrupting tau self-assembly (Arslan et al., 2026; Masri, 2026).

Single-target drugs have, frankly, had a rough run in late-stage Alzheimer’s trials — isolated BACE1 inhibitors and γ-secretase inhibitors both failed, as did several early monoclonal antibodies — and this string of disappointments has pushed the field toward multitarget-directed ligands, or MTDLs (Habtemariam, 2026; Masri, 2026; Mella et al., 2026). The underlying logic is fairly intuitive once stated: because Alzheimer’s pathology involves an interconnected web of Aβ toxicity, tau hyperphosphorylation, cholinergic depletion, metal dyshomeostasis, and oxidative stress, a single molecule engineered to engage several of these nodes at once may simply have better odds than one aimed at only one (Job et al., 2023; Mella et al., 2026; Setiawan et al., 2026). Advanced computational frameworks — quantitative structure–activity relationship models, Graph Transformer representation learning, and multi-objective reinforcement learning approaches such as EvoPlay-MuZero — now support the rational design of MTDLs that balance cholinesterase inhibition against tau anti-aggregation activity, iron chelation, and radical-scavenging capacity within a single scaffold (Huang et al., 2026; Mella et al., 2026; Zhou & Chen, 2026).

Peptidomimetic design occupies a particularly interesting niche here, since it targets protein–protein interfaces that remain, for the most part, undruggable by conventional small molecules (Al Khzem & Gomaa, 2026). Rational sequence engineering has produced D-amino acid retro-inverso peptides such as RI-AG03, built specifically to dual-cap the ₂₇₅VQIINK₂₈₀ and ₃₀₆VQIVYK₃₁₁ hotspots simultaneously (Al Khzem & Gomaa, 2026). In Drosophila tauopathy models, RI-AG03 suppressed tau oligomerization quite potently, extended survival, and — perhaps its most clinically relevant property — resisted proteolytic degradation once in systemic circulation (Al Khzem & Gomaa, 2026). Cyclic peptides such as cTau-binder and slightly larger mini-protein inhibitors, in the 35–48 residue range, take a related but distinct approach, capping the growth tips of tau protofilaments and sterically blocking lateral association and secondary nucleation (Al Khzem & Gomaa, 2026). Structural biology has informed antibody engineering in much the same way: Abskharon et al. (2023) designed bispecific nanobodies that selectively recognize and cap the ends of patient-derived tau fibrils, and Kayed et al. (2024) subsequently developed toxic-conformation-specific monoclonal antibodies — TTCM2 among them — that, when delivered intranasally via polymeric micelles, penetrate neurons and clear intracellular seed-competent tau aggregates by engaging the cytosolic antibody receptor and E3 ligase TRIM21. Figure 3 draws these modalities together schematically, showing how structurally distinct chemical strategies — small molecules, peptidomimetics, and, as described next, targeted degraders — converge on a common functional outcome: suppression of seeding and enhanced clearance of pathological tau.

2.4. Targeted Protein Degradation and Advanced Central Nervous System Delivery

A genuinely different therapeutic logic altogether comes from targeted protein degradation, executed most commonly through proteolysis-targeting chimeras, or PROTACs (Jiang et al., 2025; Zhou et al., 2026). Where a classical occupancy-based inhibitor must maintain sustained binding to an active or enzymatic pocket to exert its effect, a PROTAC instead operates catalytically (Jiang et al., 2025; Zhou et al., 2026). Structurally, a heterobifunctional PROTAC molecule links a tau-binding warhead through an optimized spacer to a moiety that recruits an E3 ubiquitin ligase — commonly von Hippel–Lindau (VHL) or Cereblon (CRBN) (Zhou et al., 2026). By bringing pathological tau into close spatial proximity with the E3 ligase, the PROTAC induces formation of a transient ternary complex, which triggers polyubiquitination of tau and directs it toward destruction by the 26S proteasome (Jiang et al., 2025; Zhou et al., 2026). Figure 4 outlines this cycle step by step, from initial ternary complex formation through polyubiquitination,

Figure 3. Convergent Structure-Guided Therapeutic Modalities Targeting Tau Aggregation and Clearance. This figure illustrates how three mechanistically distinct classes of structure-based tau therapeutics — small-molecule and coumarin intercalators, dual-capping peptidomimetics, and catalytic PROTAC degraders — each engage a pathological tau aggregate or seed through a different molecular mechanism, yet converge on the same functional outcome. Small molecules intercalate cross-β sheets and occupy the Lys280 nucleation interface; peptidomimetics sterically cap the ₂₇₅VQIINK₂₈₀ and ₃₀₆VQIVYK₃₁₁ growth tips; and PROTACs recruit E3 ubiquitin ligases for proteasomal clearance. The three converging arrows summarize the shared endpoint.

Figure 4. PROTAC-Mediated Catalytic Degradation of Pathological Tau via the Ubiquitin–Proteasome System. This figure details the catalytic mechanism by which heterobifunctional PROTAC molecules clear pathological tau. A tau-binding warhead and an E3 ubiquitin ligase-recruiting ligand (targeting CRBN or VHL), joined by an optimized linker, bring aggregated or hyperphosphorylated tau into direct spatial proximity with the E3 ligase, forming a transient ternary complex. This complex drives polyubiquitination of the bound tau species, marking it for recognition and cleavage by the 26S proteasome, after which the PROTAC molecule is released intact to catalytically repeat the cycle — the mechanistic basis for the tau-clearing activity of candidates such as QC-01-175 and C004019

proteasomal cleavage, and the eventual release of the PROTAC molecule to continue the cycle catalytically. Preclinical tau-directed PROTACs such as QC-01-175 and C004019 have already demonstrated fairly robust clearance of hyperphosphorylated and oligomeric tau in neuronal models derived from frontotemporal dementia patients and in transgenic mice, restoring synaptic plasticity and, in at least some paradigms, measurable cognitive function (Zhou et al., 2026). To accelerate the discovery of further candidates, machine-learning platforms such as PrePROTAC now use pre-trained protein language models together with random-forest classifiers to predict degradation-susceptible proteoforms directly from sequence, without waiting on structural data (Zhou et al., 2026).

Highly selective as these degraders and biologics are, getting them into the brain at all remains a formidable obstacle — arguably the central bottleneck of the entire field (Al Khzem & Gomaa, 2026; Rajkumar et al., 2026). The blood–brain barrier, formed by non-fenestrated endothelial cells joined by tight junctions, excludes upward of 98% of small-molecule drugs and essentially all large hydrophilic biologics from the brain parenchyma (Al Khzem & Gomaa, 2026; Rajkumar et al., 2026). PROTACs, unhelpfully, tend to violate Lipinski’s rule of five outright, owing to molecular weights that routinely exceed 800 Da and correspondingly high topological polar surface area, which together preclude passive transcellular diffusion (Zhou et al., 2026). Meeting this challenge has driven a wave of drug-delivery engineering. Smart nanocarriers — poly(lactic-co-glycolic acid) nanoparticles, solid lipid nanoparticles, liposomes, and neurotransmitter-derived lipidoids among them — extend circulation half-life, improve systemic stability, and can be functionalized to exploit receptor-mediated transcytosis across brain endothelium (Al Khzem & Gomaa, 2026; Rajkumar et al., 2026). Surface functionalization with brain-targeting peptides, such as the rabies-virus-glycoprotein-derived RVG29 peptide or ligands for the transferrin receptor (TfR1), substantially increases brain uptake through receptor-mediated endocytosis (Al Khzem & Gomaa, 2026). That said, TfR1-targeted shuttles are not without their own liabilities — peripheral tissue accumulation and, more seriously, reticulocyte depletion have been recurring safety concerns (Lofgren, 2024). High-throughput in vivo screening platforms, such as Manifold Bio’s mCode technology, have since identified alternative brain-endothelial receptor ‘portals,’ including one designated PX1, that appear to achieve comparable or superior parenchymal enrichment without triggering the same hematological toxicity (Lofgren, 2024). Direct nose-to-brain delivery via mucoadhesive nasal sprays or polymeric micelles offers yet another route, bypassing the blood–brain barrier altogether by exploiting the olfactory and trigeminal nerve pathways to deliver therapeutic peptides and PROTACs into the olfactory bulb and hippocampal circuitry directly (Jiang et al., 2025; Kayed et al., 2024).

2.5. Methodological Bottlenecks and Integrated Computational–Experimental Pipelines

Underlying much of the preceding discussion is a translational gap that has come to be known, only half-jokingly, as the ‘valley of death’ — the persistent disconnect between encouraging computational predictions, promising in vitro binding data, and eventual failure in human clinical trials (Esmaeilpour et al., 2026; Setiawan et al., 2026). Part of the problem is structural in a different sense: static AI models tend to over-optimize candidate molecules for enthalpy-driven binding against a single, fixed structural target, which is a reasonable simplification computationally but a poor approximation of physiological reality (Esmaeilpour et al., 2026). In an actual living system, drugs must contend with dense macromolecular crowding, competitive binding to human serum albumin, active P-glycoprotein efflux, ongoing conformational transitions in the target itself, and a surprising degree of post-translational proteoform diversity (Esmaeilpour et al., 2026; Fang et al., 2025). There is, additionally, a subtler risk worth naming: over-reliance on insufficiently validated generative models can quietly introduce dataset bias, with models repeatedly proposing familiar, narrow chemotypes — an over-representation of aromatic residues, for instance — rather than generalizing meaningfully into novel chemical space (Esmaeilpour et al., 2026; Huang et al., 2026).

The more promising response to this gap, and the one increasingly adopted across the field, is what might be called an integrated design platform — a closed feedback loop connecting computation and wet-lab experimentation rather than treating them as sequential, one-way stages (Al Khzem & Gomaa, 2026; Esmaeilpour et al., 2026). In such workflows, structural models generated by AlphaFold 3 or RoseTTAFold function as initial hypotheses rather than finished deliverables (Esmaeilpour et al., 2026; Fang et al., 2025). These predicted poses are then subjected to microsecond-scale, explicit-solvent molecular dynamics simulations, MM/PBSA free-energy calculations, and Residue Interaction Network topology analysis to probe dynamic binding stability and allosteric conformational behavior (Job et al., 2023; Miotto et al., 2025). In parallel, automated fast-flow peptide synthesis platforms with inline UV-vis monitoring can rapidly produce physical lead candidates of high structural purity, which then undergo biophysical profiling by cryo-EM, surface plasmon resonance, and hydrogen–deuterium exchange mass spectrometry — with the resulting experimental data fed back into the machine-learning models to iteratively refine scoring functions and weed out false positives (Al Khzem & Gomaa, 2026; Esmaeilpour et al., 2026; Jeyaraj et al., 2025). It is this closed-loop character, more than any single algorithmic advance, that seems likely to determine whether the current wave of AI-guided tau therapeutics ultimately reaches patients — a theme we return to, in more practical detail, in the Discussion.

3. Methods

3.1. Review Design and Reporting Framework

This paper was conceived as a narrative, structure-focused synthesis rather than a formal systematic review with meta-analysis — there simply are not, at this stage, enough comparable quantitative endpoints across small-molecule, peptidomimetic, antibody, and PROTAC studies to support pooled effect estimates. That said, we did not want the absence of a meta-analytic endpoint to become an excuse for a loosely constructed reference list, so the search, screening, and extraction steps below were run in a manner deliberately close to the PRISMA 2020 framework for scoping and narrative reviews, and are reported here in enough procedural detail that another group could, in principle, rerun the search and arrive at a substantially overlapping set of sources.

3.2. Information Sources and Search Strategy

Literature was identified through a structured search of PubMed/MEDLINE as the primary database, cross-checked against Scopus and Web of Science to capture recent structural-biology and computational-chemistry venues that index somewhat unevenly in MEDLINE, with Google Scholar used as a supplementary check for very recent (2025–2026) preprint-to-publication transitions. The core PubMed search string, adapted with minor syntax changes for the other two databases, was constructed as a Boolean combination of four concept blocks — tau biology, structural methodology, computational/AI platforms, and therapeutic modality — joined with AND, so that a record needed at least one hit within each block to be returned:

("tau proteins" OR "MAPT" OR "tau protein" OR "neurofibrillary tangles" AND ("protein aggregation" OR "amyloid" OR "fibril" OR "steric zipper" OR "oligomer" AND ("structure-based drug design" OR "cryo-EM" OR "cryogenic electron microscopy" OR "AlphaFold" OR "RoseTTAFold" OR "molecular dynamics" OR "deep learning" AND ("inhibitor" OR "peptidomimetic" OR "PROTAC" OR "nanobody" OR "multitarget-directed ligand" OR "blood-brain barrier")

The search was limited to records published between January 2020 and September 2026, a window chosen to capture the field from roughly the point at which AlphaFold 2 first became publicly available through to the present, since earlier structural work on tau was already comprehensively synthesized in prior reviews that this paper builds on rather than duplicates. No language restriction was applied at the search stage, though in practice every source that survived screening was published in English. Reference lists of the most relevant retrieved articles were also hand-searched — a fairly old-fashioned step, admittedly, but still one of the more reliable ways to catch closely related work that a keyword search alone tends to miss.

3.3. Eligibility Criteria and Study Selection

Records were included if they reported primary structural, computational, or pharmacological data on tau protein aggregation or its therapeutic targeting in the context of Alzheimer’s disease or a related tauopathy; if they described a cryo-EM structure, an AI-based structure-prediction platform, or a molecular-dynamics or network-biology analysis applied to tau or a closely related amyloidogenic protein (amyloid-beta, α-synuclein, or prion protein, included here for comparative structural context); or if they characterized a candidate therapeutic — small molecule, peptidomimetic, antibody or nanobody, PROTAC, or delivery platform — with at least in silico or in vitro structural evidence of target engagement. Conference abstracts and preprints were eligible for inclusion only where they reported original structural or pharmacological data not yet available in a peer-reviewed article, and are flagged as such in the reference list. We excluded records limited to purely clinical or epidemiological endpoints with no structural or mechanistic component, general Alzheimer’s disease reviews with no substantive tau-structural content, and non-peer-reviewed sources lacking any identifiable methodological detail.

Titles and abstracts identified by the search were screened first, followed by full-text review of any record that could plausibly meet the eligibility criteria above; disagreements about borderline records were resolved by re-reading the full text against the criteria a second time rather than by a formal adjudication panel, which is a reasonable approach for a narrative synthesis of this scope but would need to be tightened — dual independent screening, a documented kappa statistic, and so on — were this exercise repeated as a formal systematic review.

3.4. Data Extraction and Synthesis

For each included source, we extracted, where applicable: the structural target and disease context; the experimental or computational method used (cryo-EM resolution and PDB accession where available, AI platform and version, molecular dynamics timescale, or assay type); the specific aggregation hotspot, binding pocket, or delivery mechanism under investigation; the principal quantitative findings (binding affinities, docking scores, pLDDT confidence values, IC50 or Kd values, or pharmacokinetic parameters, as reported); and any explicitly stated limitations or translational barriers. These extracted fields form the basis of the four synthesis tables presented later in this paper (Tables 1–4), which group sources by structural biology and fibril polymorphism, computational and AI platforms, therapeutic modality, and CNS delivery strategy, respectively. Because the included literature spans structural biology, medicinal chemistry, pharmacology, and computational science — fields that do not always share a common outcome metric — synthesis here is necessarily narrative and thematic rather than statistical; we have tried, throughout, to be explicit about where a finding rests on robust experimental structural data (cryo-EM, crystallography) versus where it rests on computational prediction alone, since conflating the two is, in our view, one of the more common ways this kind of literature gets over-interpreted.

3.5. Reproducibility Statement

All search strings, database access dates, and the full list of included references are reported in sufficient detail  that an independent reviewer running the same PubMed query within the stated date window should be able to reconstruct a substantially similar evidence base. No proprietary or unpublished data were used at any stage of this synthesis.

4. Findings: Structural and Computational Convergence in Tau-Targeted Drug Discovery

Drawing together the literature reviewed above, four themes emerge with enough consistency across independent research groups that they are worth stating as findings in their own right, rather than leaving them scattered across the preceding narrative. Each is summarized below and anchored to the corresponding synthesis table.

4.1. High-Resolution Mapping of Tau Fibril Polymorphism and Assembly Kinetics

The single clearest finding to emerge from the cryo-EM literature is that tau aggregation is not the uniform, crystallization-like process it was once assumed to be, but rather an intrinsically polymorphic one (Table 1; Taylor & Radford, 2026). A given amino acid sequence, it turns out, can settle into a genuinely wide range of structurally distinct cross-β amyloid folds, with the outcome shaped by local physicochemical conditions, post-translational modification, and the presence of specific cellular cofactors (Table 1; Cehlar et al., 2024; Taylor & Radford, 2026). In Alzheimer’s disease specifically, tau assembles into paired helical filaments and straight filaments built around a shared C-shaped protofilament core, whereas Pick’s disease, corticobasal degeneration, progressive supranuclear palsy, and chronic traumatic encephalopathy each present their own, distinguishable filament topology (Table 1; Cehlar et al., 2024; Jeyaraj et al., 2025; Taylor & Radford, 2026) — a pattern that, on reflection, goes some way toward explaining why these disorders look and progress so differently despite sharing the same aggregating protein.

Beneath this static picture of mature folds lies a kinetic one that is arguably just as important. Time-resolved cryo-EM work, most notably by Lövestam et al. (2024), shows that both Alzheimer’s disease and chronic traumatic encephalopathy filaments pass through a shared transitional structure during early nucleation — the first intermediate amyloid (Figure 1; Cehlar et al., 2024; Taylor & Radford, 2026). This intermediate is an antiparallel dimer, stabilized by a tight cross-β interface at the ₃₀₆VQIVYK₃₁₁ hexapeptide, that subsequently undergoes secondary

Table 1. Structural Biology, Cryo-EM Resolution, and Amyloid Fibril Polymorphism in Neurodegenerative Proteopathies. This table summarizes cryo-EM-resolved fibril architectures across tau and related amyloidogenic proteins implicated in Alzheimer’s disease and other proteopathies. For each target, the table lists the dominant fold architecture, the specific aggregation-hotspot sequence motifs that nucleate assembly, the intermediate species identified through time-resolved structural studies, and the clinical relevance of the resulting polymorph. Rows are ordered from tau-specific findings toward comparative amyloid-beta and α-synuclein structural biology, and the final row highlights a soluble, pre-fibrillar phosphorylated tau species of direct biomarker relevance. Together, the entries illustrate why a single protein sequence can underlie clinically distinct neurodegenerative disorders.

Table 2. Artificial Intelligence, Deep Learning Platforms, and Computational Network Biology in Neurodrug Discovery. This table benchmarks the principal computational architectures now applied to tau and related neurodegeneration research, from general-purpose deep-learning structure predictors through graph-based network biology tools to reinforcement-learning frameworks for multi-target design. For each platform, the underlying algorithmic approach, primary application, demonstrated structural or predictive achievements, and documented methodological limitations are summarized side by side. The table is intended to help readers judge which computational tool is appropriate for a given structural question, and, just as importantly, where each tool’s predictions still require independent experimental confirmation before they can be trusted.

nucleation and solvent-guided structural maturation into the disease-specific C-shaped protofilament folds recovered from patient brain tissue (Figure 1; Cehlar et al., 2024; Taylor & Radford, 2026). This assembly process is governed throughout by the two master hexapeptide motifs already introduced — ₂₇₅VQIINK₂₈₀ and ₃₀₆VQIVYK₃₁₁ — which nucleate the inter-chain steric zippers and hydrophobic spines that give mature filaments their stability (Job et al., 2023; Cehlar et al., 2024). Notably, and perhaps clinically most important, soluble hyperphosphorylated proteoforms — pT217-tau in particular — accumulate in postsynaptic compartments and autophagic vacuoles well before mature fibrillization occurs, disrupting axonal trafficking along the way and, usefully, serving as a sensitive early fluid biomarker of synaptic degeneration (Table 1; Datta et al., 2023; Setiawan et al., 2026).

4.2. Benchmarking AI Structure-Prediction Platforms: Capabilities, Limits, and Network Topology

A second consistent finding concerns just how far AI structure prediction has come, and, in fairly candid terms, where it still falls short. Platforms such as AlphaFold 2, AlphaFold 3, and RoseTTAFold have converted computational structural biology from what was largely a descriptive, visualization-oriented discipline into something closer to a predictive engine for drug design (Table 2; Esmaeilpour et al., 2026; Jeyaraj et al., 2025). Using attention-based neural architectures — Evoformer and Pairformer modules among them — these tools extract evolutionary covariation patterns from multiple sequence alignments and translate them into three-dimensional structural predictions of near-experimental accuracy (Table 2; Jeyaraj et al., 2025; Jumper et al., 2021). AlphaFold 3 pushes this considerably further, modeling not just proteins in isolation but their interactions with nucleic acids, small-molecule ligands, ions, and post-translationally modified residues within a single unified framework (Fang et al., 2025; Jeyaraj et al., 2025).

Figure 2 lays out how these components typically connect in an applied workflow — primary sequence and post-translational modification data feeding a deep-learning prediction step, which then branches into static atomic coordinates on one side and residue interaction graphs on the other, both of which converge into downstream lead-optimization pipelines such as the Knowledge-guided Pre-trained Graph Transformer (KPGT) framework. Even so, rigorous benchmarking makes plain that intrinsically disordered proteins such as monomeric tau remain a genuine weak spot (Table 2; Al Khzem & Gomaa, 2026; Jeyaraj et al., 2025). Because these models were trained overwhelmingly on well-ordered crystal structures from the Protein Data Bank, intrinsically disordered regions routinely return pLDDT confidence scores below 50 — a signal of conformational flexibility rather than outright model failure, though the distinction is not always obvious downstream (Table 2; Cehlar et al., 2024; Jeyaraj et al., 2025). More concerning for peptide therapeutics specifically, AlphaFold 3 shows an estimated 51% chiral violation rate when modeling D-amino acid peptides, a serious limitation given that retro-inverso D-peptides represent one of the field’s more promising capping strategies (Table 2; Al Khzem & Gomaa, 2026). Static predictions, accordingly, require integration with explicit-solvent molecular dynamics, hydrogen–deuterium exchange mass spectrometry, and Residue Interaction Network analysis before allosteric pathways, node centrality, and post-translational-modification-induced flexibility can be mapped with any real confidence (Cehlar et al., 2024; Miotto et al., 2025).

Beyond single-target prediction, machine-learning architectures purpose-built for multi-target polypharmacology are beginning to change what counts as a tractable design problem. The EvoPlay-MuZero hybrid framework, for instance, pairs Monte Carlo tree search with latent-state planning reinforcement learning to automate de novo design of bispecific dual-peptide-bridging molecules (Table 2; Huang et al., 2026). By linking ApoE4-binding and Aβ-binding peptide segments through flexible alanine linkers, this framework generated a lead candidate — designated 15×25-3A — with a calculated interfacial solvation energy of −29.5 kcal/mol, a figure suggesting meaningful stabilization of the ApoE4–Aβ clearance complex (Huang et al., 2026). Separately, the Knowledge-guided Pre-trained Graph Transformer processed 2,446 distinct molecules spanning the APP, PSEN1, and VCP targets, achieving 99.35% classification accuracy for target-specific mechanistic signatures (Zhou & Chen, 2026). Perhaps the more conceptually interesting result here is that structural and electronic descriptors showed essentially zero overlap in this analysis — structural and topological features appear to drive multi-target bridging breadth, while functional-group and electronic chemistry instead determine single-target potency, a genuinely orthogonal dichotomy that may prove useful in future MTDL design (Zhou & Chen, 2026).

4.3. Structure-Guided Design and Polypharmacological Profiling of Anti-Aggregation Modalities

The therapeutic modalities that have emerged from this structural and computational work are summarized in Table 3, and taken together they illustrate a field pursuing several distinct chemical strategies in parallel rather than converging on any single ‘winning’ approach (Table 3; Al Khzem & Gomaa, 2026; Job et al., 2023). Among small-molecule inhibitors, Job et al. (2023) systematically evaluated seven piperidine-3-nitrobenzaldehyde derivatives (L1–L7) aimed at dual amyloid-beta and phosphorylated-tau inhibition. Molecular docking showed that the lead compound, L3, binds selectively to Lys280 and Lys281 on p-tau (PDB ID: 5V5B) and to Phe8 on amyloid-beta, with binding energies of −5.4 kcal/mol and −6.0 kcal/mol, respectively (Table 3; Job et al., 2023). Microsecond-scale explicit-solvent molecular dynamics simulations further confirmed that the L3–protein complex maintained a stable root-mean-square deviation trajectory comparable to the unbound apo-protein — a reasonably strong computational indication that primary nucleation was being effectively blocked rather than merely transiently disrupted (Job et al., 2023).

Figure 3 illustrates how three structurally distinct modalities — small molecules, peptidomimetics, and PROTAC degraders — ultimately converge on the same functional endpoint of seeding suppression and pathological tau clearance, despite operating through quite different molecular mechanisms. Natural coumarin scaffolds, for instance, intercalate directly into the cross-β fibril groove via π–π stacking with Phe19, disrupting aggregation through simple physical occlusion rather than covalent or high-affinity binding (Table 3; Masri, 2026). Pyrazole and pyrazolopyridine hybrids extend this into genuinely multitargeted territory, achieving nanomolar-to-submicromolar cholinesterase inhibition alongside a 75–79% reduction in Aβ1–42 aggregation and simultaneous chelation of Fe²⁺, Cu²⁺, and Zn²⁺ (Table 3; Arslan et al., 2026; Mella et al., 2026).

In the peptidomimetic space, the retro-inverso D-peptide RI-AG03 achieves dual-capping by engaging both the ₂₇₅VQIINK₂₈₀ and ₃₀₆VQIVYK₃₁₁ hotspots at once, potently suppressing tau oligomerization and improving survival in Drosophila tauopathy models (Table 3; Al Khzem & Gomaa, 2026). Cyclic peptides such as cTau-binder, along with somewhat larger mini-protein constructs, cap protofilament ends and block lateral association through comparable steric logic (Al Khzem & Gomaa, 2026). Conformation-specific immunotherapies offer a further layer of selectivity: the toxic-tau-conformation-specific antibody TTCM2 recognizes pathological seeds across Alzheimer’s disease, dementia with Lewy bodies, and progressive supranuclear palsy tissue, and — formulated into polymeric micelles for intranasal delivery — enters neurons and recruits the E3 ligase TRIM21 to drive proteasomal degradation of intracellular tau seeds, restoring cognitive function in aged tauopathy mice (Table 3; Kayed et al., 2024). Concurrently, PROTACs such as QC-01-175 and C004019 use heterobifunctional scaffolds to bring hyperphosphorylated tau into proximity with CRBN or VHL E3 ligases, achieving catalytic 26S proteasomal clearance in patient-derived neuronal models (Table 3; Jiang et al., 2025; Zhou et al., 2026).

4.4. Translational CNS Pharmacokinetics: Nanocarrier Engineering, Receptor Portals, and Nose-to-Brain Transcytosis

The fourth major finding concerns delivery, and it is, if anything, the least resolved of the four. Translating structurally validated anti-tau candidates into clinical benefit remains severely bottlenecked by the blood–brain barrier, which excludes more than 98% of small-molecule drugs and virtually all macromolecular biologics from the central nervous system (Table 4; Al Khzem & Gomaa, 2026; Rajkumar et al., 2026). As Table 4 details, smart nanotechnology-based delivery systems address this limitation chiefly through surface functionalization and receptor-mediated transcytosis. Polymeric nanoparticles built from PLGA or chitosan, solid lipid nanoparticles, nanostructured lipid carriers, and biomimetic exosomes loaded with therapeutic payload each demonstrate improved plasma stability, extended circulation half-life, and more controllable CNS release profiles relative to unmodified drug (Table 4; Rajkumar et al., 2026).

Figure 4 traces the two principal delivery routes side by side — systemic receptor-mediated transcytosis on one path, and direct nose-to-brain transport on the other — both converging on higher effective brain parenchymal exposure than either could likely achieve on its own. On the systemic route, efforts to move beyond transferrin-receptor-associated safety liabilities, chiefly reticulocyte depletion and broader hematological toxicity, have prompted development of next-generation brain shuttles (Table 4; Lofgren, 2024; Wu et al., 2024). High-throughput in vivo multiplexed screening — the mCode platform,

Table 3. Small-Molecule, Peptidomimetic, PROTAC, and Multitarget Therapeutics Targeting Tau and Amyloid Pathology. This table catalogs representative candidate therapeutics discussed in this review, organized by chemical and structural class rather than by developmental stage. Each row reports the compound or platform’s structural description, its molecular target and mechanism of action, the pharmacological or biophysical effects reported in the source study, and the principal translational bottleneck limiting its advancement. The table spans five distinct modalities — small-molecule aggregation inhibitors, multitarget-directed ligands, retro-inverso peptidomimetics, conformation-specific antibodies, and PROTAC degraders — to illustrate the mechanistic breadth of current structure-based anti-tau drug design.

Table 4. Central Nervous System Drug Delivery Platforms, Blood–Brain Barrier Permeation, and Nanotechnology Innovations. This table compares six strategies for delivering tau-targeted therapeutics across the blood–brain barrier, spanning nanoparticle-based systemic delivery, receptor-mediated transcytosis shuttles, and direct nose-to-brain routes. For each platform, the table reports its physicochemical composition and surface functionalization, the specific transport mechanism exploited, representative therapeutic cargo already delivered using that platform, and the reported efficacy and safety profile. The comparison is intended to help readers weigh trade-offs between brain-exposure gains and off-target or hematological liabilities when selecting a delivery strategy for a given therapeutic modality.

specifically — identified novel endothelial-enriched receptor ‘portals,’ PX1 among them, that appear to achieve superior parenchymal antibody delivery without the reticulocyte toxicity associated with conventional TfR1 targeting (Table 4; Lofgren, 2024). In parallel, de novo–designed ~70-residue TfR1 peptide shuttles generated via AlphaFold 2 show rapid binding kinetics to the apical domain of human TfR1, achieving CNS exposure broadly comparable to established antibody-fusion shuttles such as trontinemab (Table 4; Wu et al., 2024).

Direct nose-to-brain delivery, meanwhile, sidesteps the barrier altogether by routing therapeutics along the olfactory and trigeminal nerve pathways (Table 4; Rajkumar et al., 2026). In a physiologically realistic three-dimensional-printed human nasal cavity model, an optimized galantamine nasal spray formulation (GNT-NS, Formulation P3) achieved an olfactory-region deposition fraction of 23.85%, considerably outperforming unoptimized commercial sprays, which typically deposit only 1–5% of the dose in the deep olfactory mucosa (Table 4; Pharmaceutics, 2026). In vivo pharmacokinetic assessment confirmed that this optimized formulation substantially increased brain drug exposure relative to oral administration while reducing peripheral gastrointestinal side effects — a genuinely encouraging, if still early-stage, indication that nose-to-brain platforms might offer a translatable delivery route for CNS-targeted anti-aggregation therapies more broadly, PROTACs and peptidomimetics included.

5. From Structural Insight to Clinical Translation: Discussion and Future Outlook

5.1. What Structural Biology and AI Have Actually Changed

Stepping back from the individual findings, it is worth asking plainly what has genuinely changed in this field over the past several years, as opposed to what merely looks different on the surface. The honest answer, we think, is that tau has moved — not completely, but substantively — from being an intractable target to a merely difficult one. That shift rests on two developments working in tandem rather than either alone. Cryo-EM supplied the ground truth: real, atomic-resolution structures of pathological filaments pulled directly from patient tissue, revealing a polymorphism that no one had fully appreciated before (Figure 1; Cehlar et al., 2024; Taylor & Radford, 2026). AI structure prediction then supplied the scale — the capacity to model proteoforms, screen candidate binders, and explore chemical space far faster than crystallography or NMR alone ever could (Figure 2; Esmaeilpour et al., 2026; Jeyaraj et al., 2025; Jumper et al., 2021). Neither development would have gone nearly as far without the other. Cryo-EM structures alone are static snapshots, however beautiful; AI predictions without experimental ground truth are, at best, plausible guesses. It is the combination — the cross-validation, really — that has turned tau into a target where structure-based design is now a legitimate strategy rather than an aspiration (Table 1; Table 2).

This convergence has, in turn, licensed a genuinely broader therapeutic portfolio than the field had access to even five years ago. Where earlier drug discovery against tau was limited almost entirely to small molecules, the modalities summarized in Table 3 and illustrated in Figure 3 — small-molecule intercalators, multitarget-directed ligands, retro-inverso peptidomimetics, conformation-specific nanobodies, and catalytic PROTAC degraders — now operate on genuinely distinct mechanistic principles, occupancy-based inhibition, steric capping, and catalytic clearance among them (Al Khzem & Gomaa, 2026; Job et al., 2023; Zhou et al., 2026). We would gently push back, though, on any narrative that treats this diversification as evidence the problem is nearly solved. A wider portfolio of mechanisms is not the same thing as a validated clinical candidate, and it is worth remembering that essentially everything reviewed in Section 4 sits somewhere between preclinical and early translational stage.

5.2. Persistent Rate-Limiting Steps: Disordered Ensembles, Chirality, and the Blood–Brain Barrier

Three obstacles, in our reading of this literature, do more than any others to slow the field down, and none of them is likely to yield to incremental tinkering. The first is the disordered-ensemble problem itself. AlphaFold-family tools were, after all, trained on the Protein Data Bank’s well-ordered structures, so it should not be entirely surprising that they underperform on the very conformational flexibility that defines tau in its monomeric, pre-aggregation state (Table 2; Jeyaraj et al., 2025; Taylor & Radford, 2026). Low pLDDT scores in these regions are technically informative — they correctly flag uncertainty — but they offer little constructive guidance for a medicinal chemist trying to design a binder against a moving target. The second obstacle is more specific and, frankly, more surprising: a roughly 51% chiral violation rate for AlphaFold 3 on D-amino acid peptides is a substantial failure rate for a therapeutic class — retro-inverso peptidomimetics — that depends entirely on correct chirality to resist proteolytic degradation (Al Khzem & Gomaa, 2026). Until this gap closes, D-peptide design will likely continue to rely on template-based or physics-based modeling rather than pure deep-learning prediction, however capable those tools become for L-amino acid targets.

The third obstacle is, arguably, the one that matters most in practice, because it applies almost irrespective of how good the upstream structural biology and design work turns out to be: the blood–brain barrier. Even a perfectly selective, perfectly potent tau-degrading PROTAC is therapeutically inert if fewer than 2% of an administered dose ever reaches brain parenchyma (Table 4; Al Khzem & Gomaa, 2026; Rajkumar et al., 2026). The nanocarrier, receptor-portal, and nose-to-brain strategies summarized in Table 4 and Figure 4 represent real, measurable progress — the GNT-NS nasal formulation’s 23.85% olfactory deposition fraction, for instance, or the PX1 portal’s apparent avoidance of TfR1-associated reticulocyte toxicity (Lofgren, 2024; Pharmaceutics, 2026) — but none of these approaches has yet been validated at the scale or in the patient populations that would be needed to call the delivery problem solved. If we had to name a single rate-limiting step for the field as a whole, this would be it.

5.3. Toward Closed-Loop, Multi-Target Drug Design: A Ten-Year Roadmap

Given these constraints, what does a realistic path forward actually look like? We would suggest — and this is admittedly closer to informed extrapolation than settled consensus — that the field is converging, whether by design or simply by necessity, on three interlocking priorities over roughly the next decade (Al Khzem & Gomaa, 2026; Setiawan et al., 2026).

The first priority is bringing pharmacokinetics forward in the design process rather than treating it as a late-stage gate. Quantitative blood–brain barrier permeability, efflux-transporter susceptibility, and brain-to-plasma distribution ratios should, in our view, be built into early lead-selection algorithms from the outset, not bolted on after a promising in vitro hit has already consumed months of medicinal chemistry effort (Al Khzem & Gomaa, 2026). The second is a deeper embrace of AI-guided multi-node polypharmacology — combining generative approaches such as diffusion models and reinforcement learning with expanding human proteoform databases to design single molecular entities, whether MTDLs, bispecific degraders, or dual-peptide bridges of the kind demonstrated by EvoPlay-MuZero, that simultaneously modulate tau aggregation, amyloid-beta clearance, and neuroinflammatory microglial activation (Figure 2; Huang et al., 2026). The third, and in some ways the most immediately actionable, is biomarker-driven precision trial design: structuring clinical protocols around validated fluid biomarkers such as plasma p-tau217 and p-tau181, together with tau-PET neuroimaging, to stratify patients, confirm genuine target engagement at the earliest, presymptomatic stages of disease, and de-risk what has historically been an extremely expensive and failure-prone translational process (Datta et al., 2023; Setiawan et al., 2026).

None of these three priorities is, on its own, a new idea — each has been proposed in some form elsewhere. What does seem relatively novel, or at least underexploited so far, is the prospect of running all three simultaneously, within the kind of closed-loop computational–experimental pipeline described in Section 2.5, so that pharmacokinetic, polypharmacological, and biomarker considerations inform lead selection concurrently rather than sequentially. Whether the field actually organizes itself this way, or continues to advance along separate, loosely coordinated tracks, will likely determine how quickly — if at all — a structurally rational, disease-modifying tau therapeutic reaches the clinic within the timeframe we have sketched here.

5.4. Limitations of This study

A few limitations of this synthesis deserve honest acknowledgment. First, as a narrative rather than systematic review, our screening process — described in Section 3 — did not include dual independent screening or formal inter-rater reliability statistics, which means some degree of selection judgment inevitably shaped which sources were included. Second, several of the primary sources synthesized here are conference abstracts or very recent publications reporting early-stage computational or preclinical data, and their findings should accordingly be read as provisional rather than fully validated. Third, this review deliberately concentrates on tau; amyloid-beta, α-synuclein, and prion protein structural biology are discussed only where directly comparative (Table 1), and readers interested in a comprehensive treatment of those targets should consult the dedicated literature cited throughout. Finally, given how rapidly AI structure-prediction platforms are being updated, some of the specific performance figures cited here — chiral violation rates and pLDDT benchmarks in particular — should be understood as snapshots of current-generation tools rather than fixed properties of the underlying approach.

6. Conclusion

Tau, once considered structurally unapproachable, is no longer quite so intractable a target. Cryo-EM has revealed the polymorphic fibril architectures that distinguish Alzheimer’s disease from related tauopathies, while AlphaFold-generation platforms have made rational, structure-guided design genuinely feasible across small molecules, peptidomimetics, nanobodies, and catalytic degraders alike. Real obstacles remain, and they should not be understated: disordered-ensemble prediction is still unreliable, D-peptide chirality modeling remains error-prone, and the blood–brain barrier continues to exclude most otherwise promising candidates. What this review suggests, on balance, is that these obstacles are becoming tractable engineering problems rather than fundamental barriers — provided AI prediction is paired consistently with molecular dynamics, biophysical validation, and biomarker-guided trial design, rather than treated as a substitute for any of them. Whether that closed-loop approach reaches the clinic within the coming decade remains to be seen, but the structural foundation for disease-modifying, tau-targeted therapeutics is, for the first time, genuinely in place.

References